Evidence map›Paper›PMID 36029839›Full record

ArticleEnvironmental research2022

Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern Italy.

Antonella Amendola, Marta Canuti, Silvia Bianchi, Sudhir Kumar, Clara Fappani, Maria Gori, Daniela Colzani, Sergei L Kosakovsky Pond, Sayaka Miura, Melissa Baggieri and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Environmental research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Authors' Reply.European journal of epidemiology · 2022
    Article
  9. Article
  10. COVID-19 is a natural infectious disease.Journal of biosafety and biosecurity · 2022
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 3 countries.

Antonella AmendolaDepartment of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: antonella.amendola@unimi.it.
Marta CanutiDepartment of Health Sciences, University of Milan, 20142, Milan, Italy. Electronic address: marta.canuti@gmail.com.
Silvia BianchiDepartment of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: silvia.bianchi@unimi.it.
Sudhir KumarInstitute for Genomics and Evolutionary Medicine, Temple University, 19122, Philadelphia, USA; Department of Biology, Temple University, 19122, Philadelphia, USA; Center for Excellence in Genome Medicine and Research, King Abdulaziz University, 22252, Jeddah, Saudi Arabia. Electronic address: s.kumar@temple.edu.
Clara FappaniDepartment of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: clara.fappani@unimi.it.
Maria GoriDepartment of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: maria.gori@unimi.it.
Daniela ColzaniDepartment of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: daniela.colzani@unimi.it.
Sergei L Kosakovsky PondInstitute for Genomics and Evolutionary Medicine, Temple University, 19122, Philadelphia, USA; Department of Biology, Temple University, 19122, Philadelphia, USA. Electronic address: spond@temple.edu.
Sayaka MiuraInstitute for Genomics and Evolutionary Medicine, Temple University, 19122, Philadelphia, USA; Department of Biology, Temple University, 19122, Philadelphia, USA. Electronic address: sayaka.miura@temple.edu.
Melissa BaggieriDepartment of Infectious Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: melissa.baggieri@iss.it.
Antonella MarchiDepartment of Infectious Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: antonella.marchi@iss.it.
Elisa BorghiDepartment of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: elisa.borghi@unimi.it.
Gianvincenzo ZuccottiDepartment of Paediatrics, Children Hospital V. Buzzi, University of Milan, 20154, Milan, Italy; Romeo and Enrica Invernizzi Pediatric Research Center, University of Milan, 20154, Milan, Italy. Electronic address: gianvincenzo.zuccotti@unimi.it.
Mario C RaviglioneCentre for Multidisciplinary Research in Health Science, University of Milan, 20122, Milan, Italy. Electronic address: mario.raviglione@unimi.it.
Fabio MaguranoDepartment of Infectious Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: fabio.magurano@iss.it.
Elisabetta TanziDepartment of Health Sciences, University of Milan, 20142, Milan, Italy; Coordinated Research Center "EpiSoMI", University of Milan, 20133, Milan, Italy. Electronic address: elisabetta.tanzi@unimi.it.
University of Milan · ITIstituto Superiore di Sanità · ITTemple University · USKing Abdulaziz University · SA

Funding

Methods For Evolutionary Genomics AnalysisR35GM139540 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI Sudhir Kumar · 2021 to 2026
$2.9M
NIGMS NIH HHS R35 GM139540
6 · The paper itself

Abstract

As a reference laboratory for measles and rubella surveillance in Lombardy, we evaluated the association between SARS-CoV-2 infection and measles-like syndromes, providing preliminary evidence for undetected early circulation of SARS-CoV-2. Overall, 435 samples from 156 cases were investigated. RNA from oropharyngeal swabs (N = 148) and urine (N = 141) was screened with four hemi-nested PCRs and molecular evidence for SARS-CoV-2 infection was found in 13 subjects. Two of the positive patients were from the pandemic period (2/12, 16.7%, March 2020-March 2021) and 11 were from the pre-pandemic period (11/44, 25%, August 2019-February 2020). Sera (N = 146) were tested for anti-SARS-CoV-2 IgG, IgM, and IgA antibodies. Five of the RNA-positive individuals also had detectable anti-SARS-CoV-2 antibodies. No strong evidence of infection was found in samples collected between August 2018 and July 2019 from 100 patients. The earliest sample with evidence of SARS-CoV-2 RNA was from September 12, 2019, and the positive patient was also positive for anti-SARS-CoV-2 antibodies (IgG and IgM). Mutations typical of B.1 strains previously reported to have emerged in January 2020 (C3037T, C14408T, and A23403G), were identified in samples collected as early as October 2019 in Lombardy. One of these mutations (C14408T) was also identified among sequences downloaded from public databases that were obtained by others from samples collected in Brazil in November 2019. We conclude that a SARS-CoV-2 progenitor capable of producing a measles-like syndrome may have emerged in late June-late July 2019 and that viruses with mutations characterizing B.1 strain may have been spreading globally before the first Wuhan outbreak. Our findings should be complemented by high-throughput sequencing to obtain additional sequence information. We highlight the importance of retrospective surveillance studies in understanding the early dynamics of COVID-19 spread and we encourage other groups to perform retrospective investigations to seek confirmatory proofs of early SARS-CoV-2 circulation.

Indexed as

COVID-19MeaslesAntibodies, ViralHumansImmunoglobulin AImmunoglobulin GImmunoglobulin MItalyRetrospective StudiesRNA, ViralSARS-CoV-2Antibodies, ViralImmunoglobulin AImmunoglobulin GImmunoglobulin MRNA, ViralCOVID-19EmergenceMeaslesPandemicRashSARS-CoV-2

Identifiers

PMID36029839
PMCPMC9404229
OpenAlexW4293051217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.